H.C. Wainwright analyst Edward White lowered the firm’s price target on Valneva to $25 from $27 and keeps a Buy rating on the shares. The company this morning reported positive 12-month antibody persistence data for VLA1553, its live attenuated single shot chikungunya vaccine candidate, White tells investors in a research note. The analyst cites lower cash per share assumptions for the target drop.
Published first on TheFly
